Novo Nordisk CEO says experimental weight loss pill could become a best-in-class drug
Publishing timestamp: 2024-03-08 12:51:20
Summary
Novo Nordisk CEO believes that their experimental weight loss pill, amycretin, could become a leading treatment for obesity, following successful early-stage trial data. The pill aims to offer a more convenient and potentially cheaper alternative to their blockbuster drug Wegovy. Midstage trials are set to begin later this year with potential launch in this decade.
Sentiment: POSITIVE
Keywords: novo nordisk a/s, pharmaceuticals, biotechnology, health care industry, business news, business, biotech and pharmaceuticals,